About this Research Topic
Although progress has been made in the treatment of esophageal in recent years, the prognosis of esophageal cancer is still not satisfactory. At present, the main treatment method for resectable esophageal cancer is neoadjuvant therapy followed by surgery, with or without adjuvant therapy. There is ongoing controversy regarding the treatment modalities of neoadjuvant and adjuvant therapies. Chemotherapy combined with immunotherapy is a more widely accepted method of neoadjuvant therapy for esophageal cancer. However, some centers still use chemoradiotherapy or chemoradiotherapy combined with immunotherapy. Meanwhile, there is still no consensus on whether adjuvant therapy should be administered after neoadjuvant therapy. Some literature reports that adjuvant therapy after neoadjuvant therapy is beneficial for patient prognosis, while other studies have found the opposite result. Concurrently, the responses to neoadjuvant and adjuvant treatments vary for different esophageal cancer patients. Assessing an individual's sensitivity to neoadjuvant therapy and customizing personalized treatment modalities for individuals is of great importance.
In this Research Topic, we focus on gathering together comprehensive research on effective and personalized neoadjuvant treatment strategies for esophageal cancer, aiming at optimizing these regimens to enhance treatment efficacy and maximize patient outcomes.
Specifically, manuscripts that focus on the following sub-topics are highly welcome.
● Factors that affect the efficacy of neoadjuvant therapy
● Prognostic factors after neoadjuvant therapy
● Potential predictive marker to determine patient response to neoadjuvant therapy
● Exploration of surgical procedures after neoadjuvant therapy
● Exploration of the necessity of adjuvant therapy after neoadjuvant treatment and surgical treatment
● Exploration of the optimal adjuvant therapy regimen after neoadjuvant treatment and surgical treatment
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In this Research Topic, we focus on gathering together comprehensive research on effective and personalized neoadjuvant treatment strategies for esophageal cancer, aiming at optimizing these regimens to enhance treatment efficacy and maximize patient outcomes.
Specifically, manuscripts that focus on the following sub-topics are highly welcome.
● Factors that affect the efficacy of neoadjuvant therapy
● Prognostic factors after neoadjuvant therapy
● Potential predictive marker to determine patient response to neoadjuvant therapy
● Exploration of surgical procedures after neoadjuvant therapy
● Exploration of the necessity of adjuvant therapy after neoadjuvant treatment and surgical treatment
● Exploration of the optimal adjuvant therapy regimen after neoadjuvant treatment and surgical treatment
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Neoadjuvant, Adjuvant, Esophageal Cancer, Surgery, Esophagectomy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
